Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs
暂无分享,去创建一个
J Cummings | C. Dive | J. Cummings | F. Raynaud | C Dive | F Raynaud | L Jones | R Sugar | R. Sugar | L. Jones | Caroline Dive | Jeffrey Cummings | Florence I. Raynaud | L. Jones | R. Sugar
[1] Anthony J. DeStefano,et al. Workshop Report and Follow-Up—AAPS Workshop on Current Topics in GLP Bioanalysis: Assay Reproducibility for Incurred Samples—Implications of Crystal City Recommendations , 2009, The AAPS Journal.
[2] Caroline Dive,et al. Tumorigenesis and Neoplastic Progression Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy , 2010 .
[3] Binodh DeSilva,et al. Key elements of bioanalytical method validation for macromolecules , 2007, The AAPS Journal.
[4] Eric Woolf,et al. Best practices during bioanalytical method validation for the characterization of assay reagents and the evaluation of analyte stability in assay standards, quality controls, and study samples , 2007, The AAPS Journal.
[5] J. W. Findlay,et al. Specificity and Accuracy Data for Ligand-binding Assays for Macromolecules Should be Interpreted with Caution , 2008, The AAPS Journal.
[6] J. Weinstein,et al. Biomarkers in Cancer Staging, Prognosis and Treatment Selection , 2005, Nature Reviews Cancer.
[7] P. Workman,et al. Biomarker-Driven Early Clinical Trials in Oncology: A Paradigm Shift in Drug Development , 2009, Cancer journal.
[8] H. Soares,et al. Method Validation and Measurement of Biomarkers in Nonclinical and Clinical Samples in Drug Development: A Conference Report , 2005, Pharmaceutical Research.
[9] Daniel Figeys,et al. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers. , 2007, Advances in cancer research.
[10] Vinod P. Shah,et al. Bioanalytical Method Validation—A Revisit with a Decade of Progress , 2000, Pharmaceutical Research.
[11] P. Hubert,et al. Using tolerance intervals in pre-study validation of analytical methods to predict in-study results. The fit-for-future-purpose concept. , 2007, Journal of chromatography. A.
[12] Stephen J. Morris,et al. Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] J Cummings,et al. Biomarker method validation in anticancer drug development , 2008, British journal of pharmacology.
[14] P. Workman,et al. Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development? , 2010, Drug discovery today.
[15] Viswanath Devanarayan,et al. Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement , 2006, Pharmaceutical Research.
[16] M. Ranson,et al. Optimisation of circulating biomarkers of cell death for routine clinical use. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] Lisa M. McShane,et al. Effective Incorporation of Biomarkers into Phase II Trials , 2009, Clinical Cancer Research.
[18] Binodh DeSilva,et al. Recommendations for the Bioanalytical Method Validation of Ligand-Binding Assays to Support Pharmacokinetic Assessments of Macromolecules , 2003, Pharmaceutical Research.
[19] Dushyant V. Sahani,et al. Biomarkers of response and resistance to antiangiogenic therapy , 2009, Nature Reviews Clinical Oncology.
[20] J. W. Findlay,et al. Some important considerations for validation of ligand-binding assays. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[21] Vinod P. Shah,et al. Quantitative Bioanalytical Methods Validation and Implementation: Best Practices for Chromatographic and Ligand Binding Assays , 2007 .
[22] Paul Workman,et al. Pharmacodynamic biomarkers for molecular cancer therapeutics. , 2007, Advances in cancer research.
[23] Serge Rudaz,et al. A risk-based analysis of the AAPS conference report on quantitative bioanalytical methods validation and implementation. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[24] Hanns-Christian Mahler,et al. Protein aggregation: pathways, induction factors and analysis. , 2009, Journal of pharmaceutical sciences.
[25] J. W. Findlay,et al. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. , 2000, Journal of pharmaceutical and biomedical analysis.
[26] Max Feinberg,et al. Validation of analytical methods based on accuracy profiles. , 2007, Journal of chromatography. A.
[27] M. Ranson,et al. Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma , 2007, Cancer Chemotherapy and Pharmacology.
[28] A Yacobi,et al. Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies , 1991, European Journal of Drug Metabolism and Pharmacokinetics.
[29] Philippe Hubert,et al. New advances in method validation and measurement uncertainty aimed at improving the quality of chemical data , 2004, Analytical and bioanalytical chemistry.
[30] P. Chiap,et al. An analysis of the SFSTP guide on validation of chromatographic bioanalytical methods: progress and limitations. , 2003, Journal of pharmaceutical and biomedical analysis.